Mr Michael J. Hoy
Independent and Non-Executive Chairman
Mr Hoy has more than 30 years’ corporate experience in Australia, the United Kingdom, USA and Asia. He is Chairman of Lipotek Pty Limited and a former director of John Fairfax Holdings Limited and FXF Trust.
Mr Hoy has been a director since 7 February 2000 and Chairman since 16 March 2000.
Dr Michelle Miller, BSc, MSc, PhD GCertAppFin (Finsia)
Managing Director
Dr Miller has worked for over 25 years in the bioscience industry, with extensive experience in commercial drug development. She completed her PhD in the Faculty of Medicine at Sydney University investigating molecular models of cancer development. Her experience includes several years at Johnson and Johnson developing anti-HIV gene therapeutics through preclinical research to clinical trials. She has finance industry experience from time spent as an Investment Manager with a specialist bioscience venture capital fund.
Dr Miller was appointed as Managing Director on 21 June 2002.
Mr Michael Medway
Independent and Non-Executive Director
Mr Medway has worked in the professional accounting industry for over 30 years. He has been a Chartered Accountant for over 30 years, and his background has seen him work across various firms in Sydney and Regional NSW where he provided a range of professional accounting services to a variety of small to medium enterprises.
He is currently a Director of Maas Group Holdings Limited (ASX: MGH) which he was appointed to during its IPO process in 2020. He has also been a Director to a variety of successful small to medium sized enterprises utilising his knowledge and experience gained through his professional accounting background.
Mr Medway holds a Bachelor of Business (Accountancy) from The University of Technology, Sydney and is a graduate of the Australian Institute of Company Directors.
Mr Medway was appointed as a Director on 16 July 2025.
Dr Paul Kasian
Independent and Non-Executive Director
Dr Paul Kasian has over 30 years of experience in high level executive and non-executive leadership roles, demonstrating domestic and international success in creating and building businesses. He has strong skills in business management/development, leadership and board level decision making. He is currently Chairman of Diamond Key International. As well as having a PhD in Microbiology, he is a graduate from the Australian Institute of Company Directors.
Dr Kasian’s previous roles include: Executive Chairman at Sedarex Ltd; Executive Chairman at Genetic Technologies Ltd; Non Executive Director (and Chairman of the Audit and Risk Committee) at Atomo Diagnostics Ltd; Chairman at IODM Ltd; Executive Chairman at Zucero Therapeutics Ltd; Chief Investment Officer at HSBC Asset Management Australia.
Dr Kasian was appointed as a Director on 23 December 2025.
Dr Graeme Wald
Independent and Non-Executive Director
Dr Graeme Wald is an Industrial Chemist and has worked as a research chemist in South Africa, Israel and the USA. He became an equities analyst and while at Merril Lynch was rated the top analyst in the Pharmaceuticals and Healthcare sector in South Africa and was a member of the top-rated Global Paper & Pulp research team. In Australia he played a leading role in growing Wilson HTM’s Life Science business to the largest in the country while Head of Lifescience research. He has extensive experience in private equity and venture capital as an Investment Director at BioScience Managers, and a Partner in Fund III at OneVentures.
He has played a major role in raising more than $750M for companies in the sector and was Chairman of the Risk & Audit Committee of Nexvet Inc. while a director of the company through to its NASDAQ listing. He was also founding Chairman of Prota Therapeutics Pty Ltd and acting CEO. He is also CEO and Director of MyrioTherapeutics Pty Ltd, a Melbourne based antibody drug company developing novel antibodies for the treatment of solid tumours and is Chairman of Psaio Therapeutics, also Melbourne based that is developing novel antibodies for the treatment of prostate cancer based on Myrio technology. He is Chairman of US based Hula Therapeutics, a private company in the clinical stage of developing a treatment for paediatric neuroblastoma, using technology partly developed by Myrio.
Mr Wald was appointed as a Director on 30 March 2026.
